A systematic review of gut microbiota differences in ME/CFS and Long COVID patients
Chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS), is a difficult-to-diagnose and treat disease that has been known worldwide for several years. Long COVID Syndrome (LCS) was first used in 2020 when it was noted that some COVID-19 patients report a range of symptoms that app...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-01-01
|
| Series: | Medical Research Journal |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/medical_research_journal/article/view/105352 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS), is a difficult-to-diagnose
and treat disease that has been known worldwide for several years. Long COVID Syndrome (LCS) was
first used in 2020 when it was noted that some COVID-19 patients report a range of symptoms that
appear 3 months after onset, last at least 2 months, and are not explained by any alternative diagnosis.
Both conditions share some elements of symptomatology. The gut microbiome of both groups appears
to be altered compared to healthy patients. The purpose of this systematic review is to analyze changes
in the gut microbiota of ME/CFS and LCS patients and discuss potential similarities or differences in the
appearance of the microbiota. A growing body of evidence suggests that changes in the gut microbiota
are associated with the progression and severity of COVID-19 and post-COVID-19 syndrome, characterized
by a reduction in anti-inflammatory bacteria such as Bifidobacterium and Faecalibacterium and enrichment
of inflammation-related microbiota, including Streptococcus and Actinomyces. In addition, changes in the
gut microbiota have also been noted in CFS patients compared to healthy individuals. This article presents
and summarizes the latest evidence on the gut microbiota and its changes in metabolome after COVID-19
infection and in CFS patients. Understanding the links between the gut microbiota and COVID-19 or CFS
would provide new insights into the future management of these disease entities. |
|---|---|
| ISSN: | 2451-2591 2451-4101 |